Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials

References

• Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007;71:159-66
   PubMed Web of Science ®Google Scholar
• Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-70
   PubMed Web of Science ®Google Scholar
• Dogra G, Irish A, Chan D, Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis 2007;49:776-85
   PubMed Web of Science ®Google Scholar
• Nannayakkara PWB, van Guldener C, ter Wee PM, et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima–media thickness, endothelial function and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 2007;167:1262-70
   PubMed Web of Science ®Google Scholar
• Rizzo M, Banach M, Montalto G, Mikhailidis DP. Lipid-lowering therapies and achievement of LDL-cholesterol targets. Arch Med Sci 2012;8:598-600
   PubMed Web of Science ®Google Scholar
• Panichi V, Paoletti S, Mantuano E, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 2006;21:337-44
   PubMed Web of Science ®Google Scholar
• Collins AJ, Li S, Ma JS, et al. Cardiovascular disease in end stage renal disease patients. Am J Kidney Dis 2001;38(Suppl 1):S26-9
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(Suppl 12):S16-23
   PubMedGoogle Scholar
• Muntner P, He J, Astor BC, et al. Traditional and non-traditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005;16:529-38
   PubMed Web of Science ®Google Scholar
• Ganesh S, Stack A, Levin N, et al. Association of elevated serum PO(4), Ca x PO(4), and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8
   PubMed Web of Science ®Google Scholar
• Mallamaci F, Zoccali C, Tripei G, et al; CREED Investigators. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002;61:609-14
   PubMed Web of Science ®Google Scholar
• Yu YH, Wang Y, Dong B, et al. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia. Chin Med J 2005;118:621-6
   PubMed Web of Science ®Google Scholar
• Kasiske BL, O’Donnell MP, Schmitz PG, et al. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990;37:880-91
   PubMed Web of Science ®Google Scholar
• Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003;14:2084-91
   PubMed Web of Science ®Google Scholar
• Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002;39:283-90
   PubMed Web of Science ®Google Scholar
• Chang JW, Yang WS, Min WK, et al. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002;39:1213-17
   PubMed Web of Science ®Google Scholar
• Rocco MV, Berns JS. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850-86
   PubMed Web of Science ®Google Scholar
• Fellström BC, Jardine AG, Schmieder RE, et al; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New Eng J Med 2009;360:1395-407
   PubMed Web of Science ®Google Scholar
• Deng J, Wu Q, Liao Y, et al. Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: a systematic review and meta-analysis. Nephrology (Carlton) 2012;17:545-51
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol 2006;26:82-6
   PubMed Web of Science ®Google Scholar
• Holmberg B, Brännström M, Bucht B, et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scan J Urol Nephrol 2005;39:503-10
   PubMed Web of Science ®Google Scholar
• Goicoechea M, García de Vinuesa S, Lahera V, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006;17(12 Suppl 3):S231-5
   PubMedGoogle Scholar
• Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 2005;96:1290-2
   PubMed Web of Science ®Google Scholar
• Ichihara A, Hayashi M, Ryuzaki M, et al. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002;17:1513-17
   PubMed Web of Science ®Google Scholar
• Burmeister JE, Miltersteiner DR, Campos BM. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein. J Nephrol 2009;22:83-9
   PubMed Web of Science ®Google Scholar
• Walker RJ, Sutherland WHF, Walker HL, et al. Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. Nephrol Dial Transplant 1997;12:87-92
   PubMed Web of Science ®Google Scholar
• Mastalerz-Migas A, Reksa D, Pokorski M, et al. Comparison of a statin vs hypolipidemic diet on the oxidant status in hemodialyzed patients with chronic renal failure. J Physiol Pharmacol 2007;58(Suppl 5):363-70
   PubMed Web of Science ®Google Scholar
• Rysz J, Aronow WS, Stolarek RS, et al. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009;13:541-50
   PubMed Web of Science ®Google Scholar
• Athyros VG, Hatzitolios AI, Karagiannis A, et al; IMPERATIVE Collaborative Group. Improving the implementation of current guidelines for the management of major coronary heart disease risk factors by multifactorial intervention. The IMPERATIVE renal analysis. Arch Med Sci 2011;7:984-92
   PubMed Web of Science ®Google Scholar
• Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodial Int 2007;11:1-14
   PubMedGoogle Scholar
• Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997;12:1908-15
   PubMed Web of Science ®Google Scholar
• Guijarro C, Keane WF. Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure. Curr Opin Nephrol Hypertens 1993;2:372-9
   PubMedGoogle Scholar
• Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother 2010;11:2665-74
   PubMed Web of Science ®Google Scholar
• Yang WQ, Song NG, Ying SS, et al. Serum lipid concentrations correlate with the progression of chronic renal failure. Clin Lab Sci 1999;12:104-8
   PubMedGoogle Scholar
• Takemura T, Yoshioka K, Aya N, et al. Apolipoproteins and lipoprotein-receptors in glomeruli in human kidney diseases. Kidney Int 1993;43:918-27
   PubMed Web of Science ®Google Scholar
• Keane WF, O’Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low density lipoproteins by mesangial cells. J Am Soc Nephrol 1993;4:187-94
   PubMed Web of Science ®Google Scholar
• Coritsidis G, Rifici V, Gupta S, et al. Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 1991;39:858-66
   PubMed Web of Science ®Google Scholar
• Quenn MT, Parthasarathy S, Fong LG, Steimberg D. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-8
   PubMed Web of Science ®Google Scholar
• Hernández-Perera O, Pérez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-19
   PubMed Web of Science ®Google Scholar
• Girona J, La Ville AE, Solà R, et al. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999;83:846-51
   PubMed Web of Science ®Google Scholar
• Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557-63
   PubMed Web of Science ®Google Scholar
• Fathi R, Isbel N, Short L, et al. The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis 2004;43:45-52
   PubMed Web of Science ®Google Scholar
• Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis 2005;45:2-14
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Liberopoulos EN, Elisaf MS. Statin pleiotropy against renal injury. J Cardiometab Syndr 2009;4:E4-9
   PubMedGoogle Scholar
• Chan PCK, Robinson JD, Yeung WC, et al. Lovastatin in glomerulonephritic patients with hyperlipidemia and heavy proteinuria. Nephrol Dial Transplant 1992;7:93-9
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, et al; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
   PubMed Web of Science ®Google Scholar
• Shepherd J, Kastelein JJ, Bittner V, et al; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-54
   PubMed Web of Science ®Google Scholar
• Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65
   PubMed Web of Science ®Google Scholar
• Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96(5A):24-33F
   PubMed Web of Science ®Google Scholar
• Koc M, Dogan C, Arinsoy T, et al. Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients. Hemodial Int 2011;15:366-73
   PubMed Web of Science ®Google Scholar
• Efstratiadis G, Tziomalos K, Mikhailidis DP, et al. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008;6:93-107
   PubMed Web of Science ®Google Scholar
• Barylski M, Małyszko J, Rysz J, et al. Lipids, blood pressure, kidney – what was new in 2011? Arch Med Sci 2011;7:1055-66
   PubMed Web of Science ®Google Scholar
• Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157:251-62
   PubMed Web of Science ®Google Scholar
• Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157:263-75
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, März W, et al. for the German Diabetes and Dialysis Study Group. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48
   PubMed Web of Science ®Google Scholar
• Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006;26:523-39
   PubMed Web of Science ®Google Scholar
• Nitta K. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease. Clin Exp Nephrol 2012;16:522-9
   PubMed Web of Science ®Google Scholar
• Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol 2012;178:100-5
   PubMed Web of Science ®Google Scholar
• Heimburger O. Lipid disorders, statins and the peritoneal membrane. Contrib Nephrol 2009;163:177-82
   PubMed Web of Science ®Google Scholar
• Di Lullo L, Addesse R, Comegna C, et al. Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Adv Ther 2005;22:601-12
   PubMed Web of Science ®Google Scholar
• Dornbrook-Lavender KA, Joy MS, et al. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy 2005;25:335-44
   PubMed Web of Science ®Google Scholar
• Lins RL, Matthys KE, Billiouw JM, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol 2004;62:287-94
   PubMed Web of Science ®Google Scholar
• Fiorini F, Patrone E, Castelluccio A. Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients. Clin Ther 1994;145:213-17
   Google Scholar
• Sawara Y, Takei T, Uchida K, et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Inter Med 2008;47:1505-10
   PubMed Web of Science ®Google Scholar
• Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009;15:MS1-5
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92
   PubMed Web of Science ®Google Scholar
• Banach M, Nikfar S, Rahimi R, et al. Lipid and Blood Pressure Meta-Analysis Collaboration Group. The effects of statins on blood pressure in normotensive or hypertensive subjects -- A meta-analysis of randomized controlled trials. Int J Cardiol 2013;preprint (in press)
   Google Scholar
• Mercando AD, Lai HM, Aronow WS, et al. Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Arch Med Sci 2012;8:57-62
   PubMed Web of Science ®Google Scholar